PDS Biotechnology has completed subject recruitment for stage 1 of its Phase II trial, evaluating the systemic administration of PDS01ADC.

Head and neck cancers are among the most difficult to treat. They can be aggressive and are located near some of the body's ...

TIGIT-targeting therapies have largely disappointed in recent months, with failed studies, terminated partnerships and ...

Results from the Phase III KEYNOTE-689 trial show that adding perioperative Keytruda (pembrolizumab) to standard-of-care radiotherapy improves event-free survival in patients with resectable, locally ...

Neoadjuvant and adjuvant pembrolizumab added to standard care significantly improves event-free survival in HNSCC.

Breaking down what patients should know about each FDA therapeutic approval from June 2025 across various oncology ...

Recent FDA decisions added new options for dermatologists involved in treating patients with psoriasis, bullous pemphigoid ...

A new study led by clinician-scientists and researchers at the National Cancer Centre Singapore (NCCS) has found that the ...

Sigma Chi International Fraternity announces $31 million pledge to create the Sigma Chi Center for Advanced Therapeutics and Innovation at Huntsman Cancer Institute, the largest pledge in the ...

Dr. Gerson was reversing a vast majority of degenerative diseases, including terminal cancer: there is no sound evidence that Gerson ever reversed a single case of cancer. the world’s premier clinic ...

The disease in Brazil Head and neck cancer is a group of malignant tumors that can appear in the mouth, oropharynx, larynx, nose, sinuses, nasopharynx, eye socket, neck, and thyroid.